Stock Price Updates, Executive Appointments, Acquisitions, Orphan Drug Designations, and Preclinical Developments - Research Report on Ariad, Halozyme, DepoMed, Omeros, and BioCryst

NEW YORK, December 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Halozyme Therapeutics, Inc. (NASDAQ: HALO), DepoMed Inc. (NASDAQ: DEPO), Omeros Corporation (NASDAQ: OMER), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Ariad Pharmaceuticals Inc. Research Report

On December 18, 2013, Ariad Pharmaceuticals Inc.'s (Ariad) stock ended the day's session at $4.98, which is 19.71% higher than the previous day's closing price of $4.16. The Company's stock gained 25.13% over the past three trading days as compared to the Dow Jones Industrial Average Index, which ended 2.62% higher over the same trading period. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

Halozyme Therapeutics, Inc. Research Report  

On December 17, 2013, Halozyme Therapeutics Inc. (Halozyme) announced executive appointments. According to the Company, Helen Torley, M.B. Ch. B., M.R.C.P., will join Halozyme as President and CEO, effective January 6, 2014. Halozyme reported that Torley will also become a member of the Board of Directors. According to Halozyme, Dr. Torley most recently served as Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen. "Helen's demonstrated leadership of Onyx's oncology products will build on Halozyme's trajectory of value creation, pivoting from partnered to proprietary products," said Kenneth J. Kelley, Chairman of the Board of Directors of Halozyme. The Company stated that Gregory I. Frost, Ph.D. will be departing Halozyme as he takes on the role as Head of Intrexon's Health Sector, effective January 6, 2014, however, Dr. Frost will continue to lead Halozyme's Scientific Advisory Board. The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

DepoMed Inc. Research Report

On December 17, 2013, DepoMed Inc. (Depomed) announced the acquisition of the US rights to CAMBIA (diclofenac potassium for oral solution) from Nautilus Neurosciences (Nautilus) for $48.7 million. According to the Company, Depomed may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones. "CAMBIA, our third product acquisition in 18 months, is a unique and fast acting treatment for migraine with long-term growth potential that is a great fit in our pain and neurology-focused portfolio," said Jim Schoeneck, President and CEO of Depomed. "Some of the capital secured in October 2013 from the sale of our royalties in type 2 diabetes assets is being put to work in this product acquisition that leverages our current infrastructure. We will continue to actively seek products that complement our pain and neurology portfolio and position us for a strong growth trajectory in the coming years." The Full Research Report on DepoMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/edda_DEPO

Omeros Corporation Research Report

On December 18, 2013, Omeros Corp. (Omeros) announced that the US Food and Drug Administration (FDA) has granted an orphan drug designation to OMS721, the Company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) for the prevention of complement-mediated thrombotic microangiopathies (TMAs). "We are pleased that the FDA has granted orphan drug designation for OMS721. The designation should accelerate the development of OMS721 and, given the limitations of current treatments for TMAs, we look forward to initiating our Phase 2 clinical program next quarter," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "The remainder of this year and the first part of 2014 promise to be exciting times across other Omeros programs as well. This month we will initiate our OMS824 Phase 2 clinical program in Huntington's disease - earlier granted orphan drug designation by the FDA - and could also report Phase 2a data for OMS824 in schizophrenia. We then look to the potential marketing approval of Omidria, its launch completing our transition to a commercial company." The Full Research Report on Omeros Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e3c9_OMER

BioCryst Pharmaceuticals, Inc. Research Report

On December 18, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced the selection of two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks. According to BioCryst, the second generation discovery program's goals of improving selectivity and bioavailability compared to BCX4161 were both met, with no effect on prothrombin time at high concentrations ( > 50 micromolar), and oral fraction absorbed exceeding 25%. BioCryst also discovered that compounds demonstrate sub-nanomolar potency on the isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex vivo activated human plasma kallikrein inhibition (aPKI) assay. "We are pleased with the outcome of our discovery program for second-generation plasma kallikrein inhibitors," said Yarlagadda S. Babu, Ph.D., Senior Vice President, Drug Discovery at BioCryst. "We look forward to evaluating nonclinical safety in the preclinical development phase, and to providing updates regarding our progress towards our goal of developing a once-daily prophylactic therapy for hereditary angioedema." The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f9b1_BCRX

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.